Before a new medication is approved to treat a disease or condition, it must be investigated through a series of clinical trials in patients who have that disease or condition to determine how it works, how effective it is, and whether it is safe.
Each year, millions of people decide to participate in clinical trials for a variety of reasons:
To obtain expert medical care at a leading healthcare facility during the trial
To increase treatment options by gaining access to experimental approaches
To help others who have the same disease by contributing to medical research, contact us to learn how you can:
Identify the right clinical trial for you with a simplified qualification process and matching service
Complete a pre-screener to determine your eligibility to participate
How does the process work?
Once you’ve identified a trial that may be a good fit for you, you will complete an online pre-screener to determine if you may be eligible.
The pre-screener will include:
- General contact information
- Questions based on study criteria
As you complete the prescreener, you will be notified in the moment whether you may qualify for the trial based on your responses, and a referral coordinator will contact you to guide you through the rest of the process. Qualified patients will be connected directly to trial sites and provided with information and support along the way.
Now that you’ve learned about the importance of clinical trials, research, and how you can help, visit a list of our current trials to learn about each of them, complete their prescreeners, and have the opportunity to connect with a referral coordinator who can guide you along your journey.
SPARTA APL-101
The primary Phase 1 purpose of this study is to assess overall safety and tolerability and recommended Phase 2 dose (RP2D) of APL-101. The Phase 2 portion will assess the efficacy of the dose determined in Phase 1 in individuals with Non-Small Cell Lung Cancer with c-Met EXON 14 Skip Mutations and c-Met Dysregulation Advanced Solid Tumors.
CALM YIV-906
YIV-906 (PHY906, KD018) is an oral form of a spray-dried aqueous extract of four herbs, which have been used in the Orient for more than 1800 years for a variety of gastrointestinal symptoms including diarrhea, nausea, and vomiting. Extensive clinical and pre-clinical research has been done indicated that YIV-906 may have synergistic anticancer activities as well as GI toxicity reduction to cancer treatments, including sorafenib. The proposed plan will investigate the efficacy and mechanisms of YIV-906 as an adjuvant to sorafenib in the treatment of patients with Hepatitis B(+)-associated advanced hepatocellular carcinoma.
